Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First Time in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NST 6179 in Healthy Subjects

NCT05181085 is registered in ClinicalTrials.gov with NorthSea Therapeutics B.V. as lead sponsor.

NCT NCT05181085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05181085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First Time in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of NST 6179 in Healthy Subjects
Lead sponsor
NorthSea Therapeutics B.V.
Phase
Phase 1
Overall status
Completed
Start date
November 11, 2021
Completion date
May 27, 2022
Enrollment
70 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parenteral nutrition associated liver disease, short bowel syndrome